Ananthakrishna R, Lee SL, Foote J, et al. - This prospective, multicenter double-blind placebo-controlled randomized trial, RESOLVE-HCM, is designed to assess the impacts of perhexiline treatment on the extent of left ventricular hypertrophy (LVH) among symptomatic hypertrophic cardiomyopathy (HCM) patients with at least moderate LVH. In a randomized manner, 60 patients will be assigned to receive either perhexiline or matching placebo. Alteration in LVH, evaluated employing cardiovascular magnetic resonance imaging, following 12-months treatment with perhexiline was set as the primary endpoint. It is expected that novel information regarding the utility of perhexiline in regression of LVH in symptomatic HCM patients will be offered by this study. A positive outcome would be followed by implementation of a Phase 3 clinical trial addressing long-term impacts of perhexiline on risk of heart failure as well as mortality in HCM cases.